Dang Nicholas C, Topkara Veli K, Kim Brian T, Mercando Michelle L, Kay Joy, Naka Yoshifumi
Division of Cardiothoracic Surgery, Department of Surgery, Columbia University, College of Physicians and Surgeons, New York, NY 10032 , USA.
J Thorac Cardiovasc Surg. 2005 Nov;130(5):1302-9. doi: 10.1016/j.jtcvs.2005.07.017. Epub 2005 Oct 13.
The use of left ventricular assist devices as a bridge to transplantation for patients with chronic congestive heart failure is well accepted. However, few studies have examined outcomes solely for these patients. This study details one center's left ventricular assist device experience with this population.
Two hundred one patients received HeartMate left ventricular assist devices (Thoratec Corp, Pleasanton, Calif) from January 1, 1996, to April 30, 2004. Of these, 119 (59.2%) had chronic congestive heart failure (diagnosis >6 months) as the primary indication. Outcome parameters included early mortality after left ventricular assist device placement (<30 days), bridge-to-transplantation rate, and posttransplantation survival. Variables examined included patient demographic data; preoperative pacemaker, internal defibrillator, and balloon pump use; and preoperative laboratory values.
Advanced age, female sex, and diabetes were independent predictors of early death (P = .048, odds ratio 1.879 per 10 years of age, 95% confidence interval 1.005-3.515; P = .002, odds ratio 10.029, 95% confidence interval 2.256-44.583; P = .040, odds ratio 3.974, 95% confidence interval 1.063-14.861). Advanced age, female sex, and low preoperative albumin were independent predictors of poor bridge-to-transplantation rate (P = .029, odds ratio 0.135 per 10 years of age, 95% confidence interval 0.022-0.819; P = .002, odds ratio 0.013, 95% confidence interval 0.001-0.197; P = .023, odds ratio 19.178 per 1 g/dL albumin, 95% confidence interval 1.504-244.598). There were no independent predictors of poor posttransplantation survival and prolonged intensive care unit stay. Overall bridge-to-transplantation rate was 81.5%. The 1-, 3-, 5-, and 7-year posttransplantation survivals were 88.4%, 84.5%, 78.4%, and 76.0%.
Among patients with chronic congestive heart failure, advanced age, female sex, diabetes, and low preoperative albumin predict poor clinical course. Careful risk stratification and comprehensive evaluation by care providers should be performed for candidates who are female, are elderly, and have diabetes, and preoperative nutritional optimization should be encouraged to enhance patient outcomes.
使用左心室辅助装置作为慢性充血性心力衰竭患者移植的桥梁已被广泛接受。然而,很少有研究专门针对这些患者的结局进行考察。本研究详细介绍了一个中心在这一人群中使用左心室辅助装置的经验。
1996年1月1日至2004年4月30日期间,201例患者接受了HeartMate左心室辅助装置(Thoratec公司,加利福尼亚州普莱森顿)。其中,119例(59.2%)以慢性充血性心力衰竭(诊断超过6个月)作为主要适应证。结局参数包括左心室辅助装置置入后的早期死亡率(<30天)、移植桥接率和移植后生存率。所考察的变量包括患者人口统计学数据;术前起搏器、植入式除颤器和球囊泵的使用情况;以及术前实验室值。
高龄、女性和糖尿病是早期死亡的独立预测因素(P = 0.048,每10岁的优势比为1.879,95%置信区间为1.005 - 3.515;P = 0.002,优势比为10.029,95%置信区间为2.256 - 44.583;P =